These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 37163814)

  • 21. Selective interleukin-1 receptor-associated kinase 4 inhibitors for the treatment of autoimmune disorders and lymphoid malignancy.
    Kelly PN; Romero DL; Yang Y; Shaffer AL; Chaudhary D; Robinson S; Miao W; Rui L; Westlin WF; Kapeller R; Staudt LM
    J Exp Med; 2015 Dec; 212(13):2189-201. PubMed ID: 26621451
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identification of quinazoline based inhibitors of IRAK4 for the treatment of inflammation.
    Smith GF; Altman MD; Andresen B; Baker J; Brubaker JD; Chen H; Chen Y; Childers M; Donofrio A; Ferguson H; Fischer C; Fischmann TO; Gibeau C; Hicks A; Jin S; Kattar S; Kleinschek MA; Leccese E; Lesburg C; Li C; Lim J; Liu D; Maclean JKF; Mansoor F; Moy LY; Mulrooney EF; Necheva AS; Presland J; Rakhilina L; Yang R; Torres L; Zhang-Hoover J; Northrup A
    Bioorg Med Chem Lett; 2017 Jun; 27(12):2721-2726. PubMed ID: 28501511
    [TBL] [Abstract][Full Text] [Related]  

  • 23. USP13-mediated IRAK4 deubiquitination disrupts the pathological symptoms of lipopolysaccharides-induced sepsis.
    Wang Z; Jiang L; Zhang D; Chen D; Wang L; Xiao D
    Microbes Infect; 2021; 23(9-10):104867. PubMed ID: 34298177
    [TBL] [Abstract][Full Text] [Related]  

  • 24. IRAK4 kinase activity is not required for induction of endotoxin tolerance but contributes to TLR2-mediated tolerance.
    Xiong Y; Pennini M; Vogel SN; Medvedev AE
    J Leukoc Biol; 2013 Aug; 94(2):291-300. PubMed ID: 23695305
    [TBL] [Abstract][Full Text] [Related]  

  • 25. IRAK4 as a molecular target in the amelioration of innate immunity-related endotoxic shock and acute liver injury by chlorogenic acid.
    Park SH; Baek SI; Yun J; Lee S; Yoon DY; Jung JK; Jung SH; Hwang BY; Hong JT; Han SB; Kim Y
    J Immunol; 2015 Feb; 194(3):1122-30. PubMed ID: 25548221
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Protective Effects of Oridonin on Acute Liver Injury via Impeding Posttranslational Modifications of Interleukin-1 Receptor-Associated Kinase 4 (IRAK4) in the Toll-Like Receptor 4 (TLR4) Signaling Pathway.
    Shi M; Deng Y; Yu H; Xu L; Shi C; Chen J; Li G; Du Y; Wang YG
    Mediators Inflamm; 2019; 2019():7634761. PubMed ID: 31611735
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Small Molecule Inhibition of Interleukin-1 Receptor-Associated Kinase 4 (IRAK4).
    Genung NE; Guckian KM
    Prog Med Chem; 2017; 56():117-163. PubMed ID: 28314411
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Deficiency in IRAK4 activity attenuates manifestations of murine Lupus.
    Murphy M; Pattabiraman G; Manavalan TT; Medvedev AE
    Eur J Immunol; 2017 May; 47(5):880-891. PubMed ID: 28295231
    [TBL] [Abstract][Full Text] [Related]  

  • 29. IRAK4 kinase activity is required for Th17 differentiation and Th17-mediated disease.
    Staschke KA; Dong S; Saha J; Zhao J; Brooks NA; Hepburn DL; Xia J; Gulen MF; Kang Z; Altuntas CZ; Tuohy VK; Gilmour R; Li X; Na S
    J Immunol; 2009 Jul; 183(1):568-77. PubMed ID: 19542468
    [TBL] [Abstract][Full Text] [Related]  

  • 30. IRAK4 inhibition dampens pathogenic processes driving inflammatory skin diseases.
    Lavazais S; Jargosch M; Dupont S; Labéguère F; Menet C; Jagerschmidt C; Ohm F; Kupcsik L; Parent I; Cottereaux C; Marsais F; Oste L; Van de Water A; Christophe T; De Vos S; Fallon P; Lauffer F; Clément-Lacroix P; Eyerich K; Brys R
    Sci Transl Med; 2023 Feb; 15(683):eabj3289. PubMed ID: 36791209
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Novel 1,2,4-triazine-quinoline hybrids: The privileged scaffolds as potent multi-target inhibitors of LPS-induced inflammatory response via dual COX-2 and 15-LOX inhibition.
    Ghanim AM; Rezq S; Ibrahim TS; Romero DG; Kothayer H
    Eur J Med Chem; 2021 Jul; 219():113457. PubMed ID: 33892270
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Design of Novel IRAK4 Inhibitors Using Molecular Docking, Dynamics Simulation and 3D-QSAR Studies.
    Bhujbal SP; He W; Hah JM
    Molecules; 2022 Sep; 27(19):. PubMed ID: 36234844
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Design, synthesis, and pharmacological evaluation of N-(3-carbamoyl-1H-pyrazol-4-yl)-1,3-oxazole-4-carboxamide derivatives as interleukin-1 receptor-associated kinase 4 inhibitors with reduced potential for cytochrome P450 1A2 induction.
    Inami H; Mizutani T; Watanabe J; Hayashida H; Ito T; Terasawa T; Kontani T; Yamagishi H; Usuda H; Aoyama N; Imamura E; Ishikawa T
    Bioorg Med Chem; 2023 May; 87():117302. PubMed ID: 37201454
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeting IRAK4 for Degradation with PROTACs.
    Nunes J; McGonagle GA; Eden J; Kiritharan G; Touzet M; Lewell X; Emery J; Eidam H; Harling JD; Anderson NA
    ACS Med Chem Lett; 2019 Jul; 10(7):1081-1085. PubMed ID: 31312412
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Potent and Selective Amidopyrazole Inhibitors of IRAK4 That Are Efficacious in a Rodent Model of Inflammation.
    McElroy WT; Tan Z; Ho G; Paliwal S; Li G; Seganish WM; Tulshian D; Tata J; Fischmann TO; Sondey C; Bian H; Bober L; Jackson J; Garlisi CG; Devito K; Fossetta J; Lundell D; Niu X
    ACS Med Chem Lett; 2015 Jun; 6(6):677-82. PubMed ID: 26101573
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Discovery of Clinical Candidate 1-{[(2S,3S,4S)-3-Ethyl-4-fluoro-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide (PF-06650833), a Potent, Selective Inhibitor of Interleukin-1 Receptor Associated Kinase 4 (IRAK4), by Fragment-Based Drug Design.
    Lee KL; Ambler CM; Anderson DR; Boscoe BP; Bree AG; Brodfuehrer JI; Chang JS; Choi C; Chung S; Curran KJ; Day JE; Dehnhardt CM; Dower K; Drozda SE; Frisbie RK; Gavrin LK; Goldberg JA; Han S; Hegen M; Hepworth D; Hope HR; Kamtekar S; Kilty IC; Lee A; Lin LL; Lovering FE; Lowe MD; Mathias JP; Morgan HM; Murphy EA; Papaioannou N; Patny A; Pierce BS; Rao VR; Saiah E; Samardjiev IJ; Samas BM; Shen MWH; Shin JH; Soutter HH; Strohbach JW; Symanowicz PT; Thomason JR; Trzupek JD; Vargas R; Vincent F; Yan J; Zapf CW; Wright SW
    J Med Chem; 2017 Jul; 60(13):5521-5542. PubMed ID: 28498658
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Brazilein Suppresses Inflammation through Inactivation of IRAK4-NF-κB Pathway in LPS-Induced Raw264.7 Macrophage Cells.
    Kim KJ; Yoon KY; Yoon HS; Oh SR; Lee BY
    Int J Mol Sci; 2015 Nov; 16(11):27589-98. PubMed ID: 26593910
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 3,3'-Diindolylmethane attenuates LPS-mediated acute liver failure by regulating miRNAs to target IRAK4 and suppress Toll-like receptor signalling.
    Tomar S; Nagarkatti M; Nagarkatti PS
    Br J Pharmacol; 2015 Apr; 172(8):2133-47. PubMed ID: 25521277
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Interleukin-1 receptor-associated kinase 4 (IRAK4) plays a dual role in myddosome formation and Toll-like receptor signaling.
    De Nardo D; Balka KR; Cardona Gloria Y; Rao VR; Latz E; Masters SL
    J Biol Chem; 2018 Sep; 293(39):15195-15207. PubMed ID: 30076215
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitors: an updated patent review (2016-2018).
    McElroy WT
    Expert Opin Ther Pat; 2019 Apr; 29(4):243-259. PubMed ID: 30916602
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.